Public consultation on HPV vaccines guidance opens
This guidance covers the following areas in relation to HPV vaccination: efficacy of the nine-valent HPV vaccine, HPV vaccination in people living with HIV and HPV vaccination in males and the cost-effectiveness of extending the HPV vaccination programme to include males.
HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe
Karafillakis, E., Simas, C., Jarrett, C., Verger, P., Peretti-Watel, P., Dib, F., De Angelis, S., Takacs, J., Ali, K.A., Pastore Celentano, L., Larson, H.
Monitoring and assessing vaccine safety: A European perspective
Lopalco, P. L., Johansen, K., Ciancio, B., De Carvalho Gomes, H., Kramarz, P., Giesecke, J.
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV
Di Mario, S., Basevi, V., Lopalco, P.L., Balduzzi, S., D'Amico, R., Magrini, N.
The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey
Levy-Bruhl, D., Bousquet, V., King, L.A., O'Flanagan, D., Bacci, S., Lopalco, P., L., Salmaso, S.
Technical guidance on the Introduction of HPV vaccines in European Union countries – an update
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
Expert opinion on the Introduction of HPV Vaccines in EU Countries
This guidance report lays down the scientific basis for the potential introduction of human papillomavirus (HPV) vaccines in order to help EU Member States to make policy choices
Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.